Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.